Evidence map›Paper›PMID 18025896›Full record

Trial reportAIDS (London, England)2007

Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.

Colleen Hadigan, Sasha Mazza, Dana Crum, Steven Grinspoon

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Treatment of dyslipidemia in HIV.Current atherosclerosis reports · 2015
    Review
  3. Dyslipidemia and lipid management in HIV-infected patients.Current opinion in endocrinology, diabetes, and obesity · 2011
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Colleen HadiganNational Institute of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Immunoregulation, Bethesda, Maryland, USA.
Sasha Mazza
Dana Crum
Steven Grinspoon
National Institute of Allergy and Infectious Diseases · US

Funding

Zoledronic Acid in Treatment of Osteoporosis in PostmenoM01RR002635 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · PI GARBER, JUDY E. · 1985 to 2008
$48.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
ZINC KINETICS STUDIES WITH STABLE ZINCM01RR000088 · NCRR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YOUNG, VERNON R · 1985 to 2001
$2.5M
MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDSR01DK059535 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN KYLE · 2000 to 2004
$2.2M
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROMEK23DK002844 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HADIGAN, COLLEEN M · 2000 to 2004
$648k
NCRR NIH HHS M01 RR000088NCRR NIH HHS M01 RR002635NCRR NIH HHS MO1 RR 02635NCRR NIH HHS MO1 RR 300088NIDDK NIH HHS K23 DK002844NIDDK NIH HHS K23 DK 20844NIDDK NIH HHS P30 DK040561NIDDK NIH HHS R01 DK059535NIDDK NIH HHS R01 DK 59535
6 · The paper itself

Abstract

After 12 weeks of rosiglitazone treatment, significant increases in total and small dense low-density lipoprotein, and the total: high-density lipoprotein (HDL)-cholesterol ratio were found. The large HDL concentration and HDL particle size decreased significantly with rosiglitazone compared with placebo. These data indicate the production of a more atherogenic lipid profile with rosiglitazone, a consideration when selecting treatment for the growing population of HIV-infected patients with type 2 diabetes and dyslipidemia.

Indexed as

AdultFemaleFollow-Up StudiesHIV-Associated Lipodystrophy SyndromeHumansHypoglycemic AgentsInsulin ResistanceLipoproteins, HDLLipoproteins, LDLMaleMiddle AgedParticle SizePPAR gammaRosiglitazoneThiazolidinedionesHypoglycemic AgentsLipoproteins, HDLLipoproteins, LDLPPAR gammaRosiglitazoneThiazolidinediones

Identifiers

PMID18025896
PMCPMC4391618
OpenAlexW2045562610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.